Jamie Weisman

3.4k total citations
16 papers, 716 citations indexed

About

Jamie Weisman is a scholar working on Dermatology, Surgery and Immunology and Allergy. According to data from OpenAlex, Jamie Weisman has authored 16 papers receiving a total of 716 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Dermatology, 5 papers in Surgery and 5 papers in Immunology and Allergy. Recurrent topics in Jamie Weisman's work include Dermatology and Skin Diseases (10 papers), Psoriasis: Treatment and Pathogenesis (5 papers) and Colorectal and Anal Carcinomas (5 papers). Jamie Weisman is often cited by papers focused on Dermatology and Skin Diseases (10 papers), Psoriasis: Treatment and Pathogenesis (5 papers) and Colorectal and Anal Carcinomas (5 papers). Jamie Weisman collaborates with scholars based in United States, Germany and Canada. Jamie Weisman's co-authors include Gregor B. E. Jemec, Christos C. Zouboulis, Errol P. Prens, David Williams, Yihua Gu, Peter Foley, Martin M. Okun, Charles Lynde, Robert Gniadecki and Eric L. Simpson and has published in prestigious journals such as Journal of the American Academy of Dermatology, Journal of the European Academy of Dermatology and Venereology and Experimental Dermatology.

In The Last Decade

Jamie Weisman

16 papers receiving 710 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jamie Weisman United States 12 596 225 219 172 141 16 716
Paolo Dapavo Italy 19 532 0.9× 120 0.5× 588 2.7× 54 0.3× 139 1.0× 82 938
Teresa Battista Italy 14 351 0.6× 102 0.5× 266 1.2× 23 0.1× 86 0.6× 41 527
Wendell C. Valdecantos United States 17 386 0.6× 28 0.1× 503 2.3× 50 0.3× 76 0.5× 32 618
Ziqian Geng United States 9 552 0.9× 191 0.8× 706 3.2× 16 0.1× 219 1.6× 14 1.1k
Mario Valenti Italy 14 250 0.4× 24 0.1× 267 1.2× 56 0.3× 54 0.4× 64 445
G. Solano‐López Spain 10 129 0.2× 50 0.2× 193 0.9× 30 0.2× 47 0.3× 20 328
Jeffrey Zweegers Netherlands 14 245 0.4× 86 0.4× 455 2.1× 17 0.1× 25 0.2× 19 610
Lieke J. van Vugt Netherlands 10 136 0.2× 45 0.2× 182 0.8× 15 0.1× 49 0.3× 12 301
Stephanie L. Roseti United States 5 135 0.2× 145 0.6× 306 1.4× 247 1.4× 10 0.1× 14 848
Jennifer DeSimone United States 10 316 0.5× 74 0.3× 164 0.7× 253 1.5× 113 0.8× 24 620

Countries citing papers authored by Jamie Weisman

Since Specialization
Citations

This map shows the geographic impact of Jamie Weisman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamie Weisman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamie Weisman more than expected).

Fields of papers citing papers by Jamie Weisman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamie Weisman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamie Weisman. The network helps show where Jamie Weisman may publish in the future.

Co-authorship network of co-authors of Jamie Weisman

This figure shows the co-authorship network connecting the top 25 collaborators of Jamie Weisman. A scholar is included among the top collaborators of Jamie Weisman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamie Weisman. Jamie Weisman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Paller, Amy S., Carsten Flohr, Lawrence F. Eichenfield, et al.. (2023). Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study. Dermatology and Therapy. 13(7). 1517–1534. 26 indexed citations
2.
Garg, Amit, Haley B. Naik, Afsáneh Alavi, et al.. (2022). Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims Data. Dermatology and Therapy. 13(2). 581–594. 6 indexed citations
3.
Blauvelt, Andrew, Emma Guttman‐Yassky, Amy S. Paller, et al.. (2022). Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). American Journal of Clinical Dermatology. 23(3). 365–383. 62 indexed citations
4.
Kimball, Alexa B., Christian Loesche, Errol P. Prens, et al.. (2022). IL‐17A is a pertinent therapeutic target for moderate‐to‐severe hidradenitis suppurativa: Combined results from a pre‐clinical and phase II proof‐of‐concept study. Experimental Dermatology. 31(10). 1522–1532. 32 indexed citations
5.
Glatt, Sophie, Gregor B. E. Jemec, Seth Forman, et al.. (2021). Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa. JAMA Dermatology. 157(11). 1279–1279. 112 indexed citations
6.
Silverberg, Jonathan I., Mark Boguniewicz, Jill Waibel, et al.. (2021). Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16. Dermatology and Therapy. 12(1). 137–148. 7 indexed citations
7.
Gooderham, Melinda, Jamie Weisman, Orin M. Goldblum, et al.. (2021). 25977 Selected infection topics in adult patients with moderate-to-severe atopic dermatitis treated with baricitinib. Journal of the American Academy of Dermatology. 85(3). AB77–AB77. 2 indexed citations
8.
Poulin, Yves, et al.. (2020). Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. 34(7). 1500–1509. 16 indexed citations
9.
Bieber, Thomas, Jacob P. Thyssen, Kristian Reich, et al.. (2020). Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. Journal of the European Academy of Dermatology and Venereology. 35(2). 476–485. 110 indexed citations
10.
Guenther, Lyn, Alison Potts Bleakman, Jamie Weisman, et al.. (2019). Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Acta Dermato Venereologica. 100(1). 1–9. 21 indexed citations
11.
Alexis, Andrew, Marta I. Rendon, Jonathan I. Silverberg, et al.. (2019). Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials. PubMed. 18(8). 804–813. 43 indexed citations
12.
Zouboulis, Christos C., Martin M. Okun, Errol P. Prens, et al.. (2018). Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. Journal of the American Academy of Dermatology. 80(1). 60–69.e2. 136 indexed citations
13.
Blauvelt, Andrew, Kim Papp, C.E.M. Griffiths, et al.. (2017). Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). American Journal of Clinical Dermatology. 18(2). 273–280. 31 indexed citations
14.
Zouboulis, Christos C., Martin M. Okun, Robert Gniadecki, et al.. (2017). Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER). SKIN The Journal of Cutaneous Medicine. 1. s128–s128. 1 indexed citations
15.
Takeshita, Junko, Shuwei Wang, Daniel B. Shin, et al.. (2014). Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting. Journal of the American Academy of Dermatology. 71(6). 1167–1175. 17 indexed citations
16.
Yeung, Howa, Joy Wan, Abby S. Van Voorhees, et al.. (2012). Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. Journal of the American Academy of Dermatology. 68(1). 64–72. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paolo Dapavo Breakdown of academic impact, for papers by Teresa Battista Breakdown of academic impact, for papers by Wendell C. Valdecantos Breakdown of academic impact, for papers by Ziqian Geng Breakdown of academic impact, for papers by Mario Valenti Breakdown of academic impact, for papers by G. Solano‐López Breakdown of academic impact, for papers by Jeffrey Zweegers Breakdown of academic impact, for papers by Lieke J. van Vugt Breakdown of academic impact, for papers by Stephanie L. Roseti Breakdown of academic impact, for papers by Jennifer DeSimone
Rankless by CCL
2026